KYOWA KIRIN

October 30, 2018

Kyowa Hakko Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary (IFRS)
Fiscal 2018 Third Quarter

(January 1, 2018 - September 30, 2018)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on October 30, 2018 for the first nine months of Fiscal 2018, from January 1, 2018 to September 30, 2018.
- This document is an English translation of parts of the Japanese-language original. The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- Figures presented in these materials have been rounded to the nearest tenth.
- Figures inside parenthesis presented in these materials indicate negative values.

Index Page

The average exchange rates for each period were as follows:

Unit: Yen

	FY 2017 results		FY 2018 results	FY 2018 forecasts
	Jan - Sep	Jan - Dec	Jan - Sep	Jan - Dec
USD	112	112	109	110
EUR	124	126	131	130
GBP	142	144	149	150

Contact
Kyowa Hakko Kirin Co., Ltd.
Corporate Communications Department
Tel +81 3 5205 7206

I. Consolidated Financial Results (IFRS)

1. Trends in consolidated profit

Unit: Billions of yen

	FY 2017 results		FY 2018 results		FY 2018 forecasts	
	Jan - Sep	Jan - Dec	Jan - Sep	Change amount	Jan - Dec	%
Revenue	261.3	353.4	253.9	(7.3)	335.0	95%
Cost of sales	(96.3)	(129.1)	(88.0)	8.3	(114.0)	88%
Gross profit	165.0	224.3	166.0	1.0	221.0	99%
Selling, general and administrative expenses	(81.4)	(113.0)	(85.9)	(4.5)	(117.0)	104%
Research and development expenses	(35.8)	(49.2)	(34.4)	1.4	(49.5)	101%
Share of profit (loss) of investments accounted for using equity method	(3.1)	(4.5)	0.3	3.4	(0.5)	11%
Core operating profit	44.7	57.7	45.9	1.3	54.0	94%
Other income	1.2	6.6	18.5	17.3		
Other expenses	(2.3)	(8.4)	(1.1)	1.2		
Finance income (costs)	0.2	(0.1)	(0.5)	(0.7)		
Profit before tax	43.7	55.8	62.8	19.0	71.0	127%
Income tax expense	(14.3)	(13.0)	(15.4)	(1.1)		
Profit	29.5	42.9	47.4	18.0	52.0	121%
EPS (¥/share)	53.83	78.38	86.62	32.79	94.99	-
Annual dividend (¥/share)		27.00			30.00	-
Dividend payout ratio (%)		34.4			31.6	-
ROE (%)		7.2				-

* "FY 2018 forecasts" in these materials, excluding those of share of profit (loss) of investments accounted for using equity method, core operating profit, profit before tax, profit, EPS, and dividend payout ratio, which have been revised, still remain unchanged from the earnings forecasts released on February 8, 2018.

2. Revenue by geographic region

Unit: Billions of yen

	FY 2017 results			FY 2018 results		FY 2018 forecasts	
	Jan - Sep	Jan - Dec	Percentage of consolidated revenue	Jan - Sep	Percentage of consolidated revenue	Jan - Dec	Percentage of consolidated revenue
Japan	178.8	240.9	68.2%	164.9	65.0%	221.2	66.0%
International	82.5	112.5	31.8%	89.0	35.0%	113.8	34.0%
Americas	16.6	24.7	7.0%	21.6	8.5%	29.7	8.9%
Europe	42.4	56.0	15.8%	42.7	16.8%	55.2	16.5%
Asia	22.4	30.2	8.6%	24.0	9.4%	28.0	8.3%
Others	1.0	1.6	0.5%	0.6	0.2%	0.9	0.3%
Total consolidated revenue	261.3	353.4	100%	253.9	100%	335.0	100%

* Revenue is classified by region or country based on location of customer.

3. Other trends

(1) Research and development expenses

Unit: Billions of yen

	FY 2017 results		FY 2018 results	FY 2018 forecasts
	Jan - Sep	Jan - Dec	Jan - Sep	Jan - Dec
Research and development (R&D) expenses	35.9	49.2	34.5	49.5
R&D expenses to revenue ratio	*13.7%*	*13.9%*	*13.6%*	*14.8%*
Pharmaceuticals	33.6	46.1	32.3	46.5
R&D expenses to revenue ratio	*16.5%*	*16.7%*	*16.3%*	*17.7%*
Bio-Chemicals	2.3	3.1	2.2	3.0

(2) Capital expenditures (property, plant and equipment)

Unit: Billions of yen

	FY 2017 results		FY 2018 results	FY 2018 forecasts
	Jan - Sep	Jan - Dec	Jan - Sep	Jan - Dec
Capital expenditures	9.9	14.3	8.1	12.5
Pharmaceuticals	5.3	6.6	3.3	5.3
Bio-Chemicals	4.6	7.7	4.8	7.2

(3) Depreciation and amortization (property, plant and equipment and intangible assets)

Unit: Billions of yen

	FY 2017 results		FY 2018 results	FY 2018 forecasts
	Jan - Sep	Jan - Dec	Jan - Sep	Jan - Dec
Depreciation and amortization	16.4	22.0	16.0	24.6
Amortization of intangible assets	*5.8*	*7.8*	*6.3*	*9.1*
Pharmaceuticals	11.4	15.3	11.7	17.3
Amortization of intangible assets	*5.7*	*7.7*	*6.2*	*9.1*
Bio-Chemicals	5.0	6.7	4.4	7.3

II. Consolidated Statement of Cash Flows (IFRS)

Unit: Billions of yen

	FY 2017 results		FY 2018 results	
	Jan - Sep	Jan - Dec	Jan - Sep	Change amount
Cash flows from operating activities	49.1	64.9	46.4	(2.7)
Cash flows from investing activities	(35.0)	(45.3)	(30.8)	4.2
Cash flows from financing activities	(13.9)	(18.3)	(16.5)	(2.6)
Effect of exchange rate changes on cash and cash equivalents	1.1	1.3	(0.4)	(1.5)
Net increase (decrease) in cash and cash equivalents	1.3	2.7	(1.3)	(2.6)
Transfer to assets held for sale	(0.0)	(1.1)	1.1	1.1
Cash and cash equivalents at beginning of period	13.1	13.1	14.7	1.6
Cash and cash equivalents at end of period*	14.4	14.7	14.5	0.1

* Cash reserves at end of period

	Cash and cash equivalents at end of period	14.4	14.7	14.5	0.1
+	Loans receivable from parent in excess of three months	135.2	143.2	179.6	44.4
+	Time deposits whose maturity periods exceed three months	0.0	0.0	0.0	0.0
	Cash reserves at end of period	149.6	157.9	194.1	44.5

III. Core Operating Profit or Loss by Segment (IFRS)

1. Pharmaceuticals segment

Unit: Billions of yen

	FY 2017 results		FY 2018 results		FY 2018 forecasts	
	Jan - Sep	Jan - Dec	Jan - Sep	Change amount	Jan - Dec	%
Revenue	203.0	275.8	197.7	(5.3)	262.0	95%
Revenue from external customers	202.3	274.8	196.9	(5.4)	261.0	95%
Japan	147.1	197.8	134.3	(12.8)	181.0	91%
International	55.2	76.9	62.6	7.4	80.0	104%
International revenue ratio	27%	28%	32%	-	31%	-
Americas	9.3	15.0	14.6	5.3	20.8	138%
Europe	31.4	41.5	31.8	0.4	39.8	96%
Asia	14.1	19.6	16.2	2.1	18.8	96%
Others	0.5	0.8	0.1	(0.4)	0.6	82%
Inter-segment revenue	0.7	1.0	0.8	0.0	1.0	101%
Cost of sales	(58.8)	(79.1)	(53.9)	4.9	(70.0)	89%
Gross profit	144.2	196.7	143.8	(0.4)	192.0	98%
Selling, general and administrative expenses	(68.3)	(95.5)	(72.3)	(4.0)	(99.0)	104%
Research and development expenses	(33.6)	(46.1)	(32.3)	1.3	(46.5)	101%
Share of profit (loss) of investments accounted for using equity method	(3.1)	(4.5)	0.3	3.4	(0.5)	11%
Core operating profit	39.2	50.5	39.5	0.3	46.0	91%

* Revenue is classified by region or country based on location of customer.

* The figures represent amounts before elimination of inter-segment transactions.

2. Bio-Chemicals segment

Unit: Billions of yen

	FY 2017 results		FY 2018 results		FY 2018 forecasts	
	Jan - Sep	Jan - Dec	Jan - Sep	Change amount	Jan - Dec	%
Revenue	60.7	81.1	58.4	(2.3)	76.0	94%
Revenue from external customers	59.0	78.6	57.0	(2.0)	74.0	94%
Japan	31.7	43.0	30.7	(1.0)	40.2	93%
International	27.3	35.6	26.3	(1.0)	33.8	95%
International revenue ratio	46%	45%	46%	-	46%	-
Americas	7.4	9.7	7.1	(0.3)	9.0	93%
Europe	11.0	14.4	11.0	(0.0)	15.4	107%
Asia	8.3	10.7	7.8	(0.5)	9.2	86%
Others	0.5	0.8	0.5	(0.0)	0.3	32%
Inter-segment revenue	1.7	2.5	1.4	(0.3)	2.0	79%
Cost of sales	(40.0)	(53.3)	(36.5)	3.5	(47.0)	88%
Gross profit	20.6	27.8	21.9	1.2	29.0	104%
Selling, general and administrative expenses	(13.2)	(17.6)	(13.7)	(0.5)	(18.0)	102%
Research and development expenses	(2.3)	(3.1)	(2.2)	0.0	(3.0)	98%
Core operating profit	5.2	7.2	6.0	0.8	8.0	111%

* Revenue is classified by region or country based on location of customer.

* The figures represent amounts before elimination of inter-segment transactions.

IV. Revenue from Main Products of Pharmaceuticals Segment (IFRS)

<Accumulative>

Unit: Billions of yen

	Indication / Product name	FY 2017 results		FY 2018 results		FY 2018 forecasts	
		Jan - Sep	Jan - Dec	Jan - Sep	Change amount	Jan - Dec	%
Japan	*Renal anemia treatment drug* ***Nesp***	41.0	56.3	39.2	(1.8)	52.4	93%
	Secondary hyperparathyroidism ***Regpara***	13.9	18.5	10.7	(3.2)	13.2	71%
	Secondary hyperparathyroidism ***Orkedia***	-	-	1.1	1.1	3.5	-
	Secondary hyperparathyroidism ***Rocaltrol***	3.0	4.1	2.8	(0.2)	3.5	87%
	Type-2 diabetes ***Onglyza***	5.2	7.3	5.4	0.1	7.6	103%
	Cardiovascular (Hypertension & angina pectoris) ***Coniel***	4.7	6.3	3.6	(1.1)	4.9	77%
	Agent for decreasing the incidence of febrile neutropenia ***G-Lasta***	12.8	18.1	14.8	2.0	20.1	111%
	Transdermal persistent pain ***Fentos***	4.3	6.0	4.0	(0.4)	5.7	96%
	Anticancer ***Poteligeo***	1.4	1.9	1.3	(0.0)	1.8	95%
	Anticancer ***Rituximab BS [KHK]***	-	-	2.4	2.4	3.2	-
	Chronic idiopathic thrombocytopenic purpura ***Romiplate***	2.5	3.4	2.4	(0.1)	3.4	100%
	Antiallergenic ***Allelock***	12.2	15.9	9.7	(2.4)	11.7	74%
	Antiallergic eyedrops ***Patanol***	10.8	12.8	11.5	0.7	12.1	94%
	Ulcerative colitis ***Asacol***	3.2	4.2	2.2	(1.0)	3.4	80%
	Psoriasis vulgaris ***Dovobet***	3.9	5.3	4.2	0.3	6.2	117%
	Psoriasis ***Lumicef***	0.5	1.0	1.4	0.9	2.7	281%
	Parkinson's disease ***Nouriast***	6.1	8.5	6.8	0.7	9.4	111%
	Antiepileptic ***Depakene***	4.8	6.5	4.0	(0.9)	5.4	82%
	Technology out-licensing	2.8	2.4	2.2	(0.6)	4.6	191%
International	*Renal anemia treatment drug* ***Nesp***	4.3	5.7	4.7	0.3	5.8	103%
	Secondary hyperparathyroidism ***Regpara***	1.6	2.2	2.3	0.7	2.8	123%
	Agent for decreasing the incidence of febrile neutropenia ***Neulasta/Peglasta***	1.5	2.0	1.7	0.2	2.0	101%
	Neutropenia treatment drug ***Gran***	3.8	5.2	4.2	0.3	4.4	86%
	X-linked hypophosphatemia (XLH) ***Crysvita***	-	-	3.6	3.6		-
	Cancer pain ***Abstral***	8.8	11.9	9.5	0.7	13.2	111%
	Cancer pain ***PecFent***	3.1	4.1	3.2	0.2	5.2	128%
	Anticancer ***Mitomycin-C***	2.5	3.4	1.7	(0.7)	2.0	57%
	Chemotherapy-induced nausea and vomiting drug ***Sancuso***	2.0	3.0	2.1	0.0	2.8	92%
	Opioid-induced constipation (OIC) ***Moventig***	0.5	0.8	1.0	0.5	2.4	299%
	Replacement therapy with testosterone for male hypogonadism ***Tostran/Fortesta***	1.7	2.2	2.1	0.4	2.1	93%
	Osteoporosis drug ***Adcal-D3***	2.6	3.6	2.7	0.0	3.3	93%
	Technology out-licensing	10.8	16.0	13.9	3.1	17.3	108%

* Revenue is classified as Japan or International (other than Japan) based on customer location.

* Revenue listed as “Technology out-licensing” specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

IV. Revenue from Main Products of Pharmaceuticals Segment (IFRS)

<Quarterly>

Unit: Billions of yen

	Indication / Product name	FY 2017 results			FY 2018 results			
		Jan - Mar	Apr - Jun	Jul - Sep	Jan - Mar	Apr - Jun	Jul - Sep	Change amount
Japan	*Renal anemia treatment drug* ***Nesp***	12.5	14.2	14.4	12.0	13.6	13.6	(0.7)
	Secondary hyperparathyroidism ***Regpara***	4.6	4.8	4.5	3.6	4.2	2.9	(1.5)
	Secondary hyperparathyroidism ***Orkedia***	-	-	-	-	0.4	0.8	0.8
	Secondary hyperparathyroidism ***Rocaltrol***	0.9	1.0	1.0	0.9	1.0	0.9	(0.1)
	Type-2 diabetes ***Onglyza***	1.6	1.8	1.9	1.6	1.9	1.8	0.0
	Cardiovascular (Hypertension & angina pectoris) ***Coniel***	1.6	1.6	1.5	1.2	1.3	1.1	(0.4)
	Agent for decreasing the incidence of febrile neutropenia ***G-Lasta***	3.8	4.3	4.6	4.3	5.1	5.3	0.7
	Transdermal persistent pain ***Fentos***	1.3	1.6	1.4	1.2	1.4	1.4	(0.1)
	Anticancer ***Poteligeo***	0.4	0.5	0.4	0.4	0.5	0.4	0.0
	Anticancer ***Rituximab BS [KHK]***	-	-	-	0.3	0.8	1.3	1.3
	Chronic idiopathic thrombocytopenic purpura ***Romiplate***	0.8	0.9	0.8	0.7	0.8	0.8	0.0
	Antiallergenic ***Allelock***	5.6	3.5	3.0	4.6	2.9	2.3	(0.8)
	Antiallergic eyedrops ***Patanol***	7.0	1.8	1.9	7.7	2.0	1.7	(0.2)
	Ulcerative colitis ***Asacol***	1.0	1.1	1.1	0.7	0.8	0.7	(0.4)
	Psoriasis vulgaris ***Dovobet***	1.2	1.4	1.2	1.2	1.6	1.4	0.2
	Psoriasis ***Lumicef***	0.1	0.1	0.3	0.4	0.5	0.5	0.2
	Parkinson's disease ***Nouriast***	1.8	2.1	2.1	1.9	2.5	2.4	0.3
	Antiepileptic ***Depakene***	1.6	1.7	1.6	1.3	1.4	1.3	(0.3)
	Technology out-licensing	0.8	1.2	0.8	1.1	0.4	0.8	(0.1)
International	*Renal anemia treatment drug* ***Nesp***	1.4	1.5	1.5	1.5	1.6	1.6	0.1
	Secondary hyperparathyroidism ***Regpara***	0.5	0.5	0.6	0.7	0.8	0.9	0.3
	Agent for decreasing the incidence of febrile neutropenia ***Neulasta/Peglasta***	0.5	0.5	0.5	0.4	0.6	0.7	0.2
	Neutropenia treatment drug ***Gran***	1.0	1.3	1.5	1.4	1.3	1.5	0.0
	X-linked hypophosphatemia (XLH) ***Crysvita***	-	-	-	-	0.8	2.7	2.7
	Cancer pain ***Abstral***	2.9	2.8	3.1	3.4	3.1	3.1	0.0
	Cancer pain ***PecFent***	1.1	0.9	1.1	1.0	1.0	1.2	0.1
	Anticancer ***Mitomycin-C***	0.8	0.8	0.9	0.6	0.6	0.5	(0.4)
	Chemotherapy-induced nausea and vomiting drug ***Sancuso***	0.6	0.7	0.7	0.6	0.7	0.8	0.1
	Opioid-induced constipation (OIC) ***Moventig***	0.2	0.1	0.2	0.3	0.3	0.4	0.2
	Replacement therapy with testosterone for male hypogonadism ***Tostran/Fortesta***	0.4	0.6	0.6	0.6	0.8	0.7	0.1
	Osteoporosis drug ***Adcal-D3***	0.8	0.9	0.9	0.9	0.9	0.9	(0.1)
	Technology out-licensing	8.0	1.6	1.3	6.5	5.9	1.5	0.2

* Revenue is classified as Japan or International (other than Japan) based on customer location.

* Revenue listed as "Technology out-licensing" specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

Ⅴ. R&D Pipeline

Filed • Approved

antibody protein small molecule

As of Sep. 30, 2018

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology	protein	**KRN321** **Darbepoetin Alfa** **Injection**	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
Oncology	antibody	**KW-0761** **Mogamulizumab** **Injection**	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	Approved in US	In-House	POTELLIGENT®
				Cutaneous T-cell Lymphoma	Filed in EU		
					Approved in JP		Additional Indication, Dosage and Administration
Immunology/Allergy	antibody	**KHK4827** **Brodalumab** **Injection**	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in KR	Kirin-Amgen	
					Approved in TH		
					Filed in SG		
					Filed in MY		
					Filed in HK		
Central Nervous System	small molecule	**KW-6002** **Istradefylline** **Oral**	Adenosine A_{2A} Receptor Antagonist	Parkinson's Disease	NDA in preparation in US	In-House	
Other	antibody	**◎KRN23** **Burosumab** **Injection**	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in CA	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
	protein	**AMG531** **Romiplostim** **Injection**	Thrombopoietin Receptor Agonist	Aplastic Anemia	Filed in JP	Kirin-Amgen	

Phase Ⅱ, Phase Ⅲ

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology	small molecule	**◎RTA 402** **Bardoxolone Methyl** **Oral**	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	Phase Ⅲ in JP	Licensed from Reata	
	small molecule	**KHK7580** **Evocalcet** **Oral**	Calcium Receptor Agonist	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Phase Ⅲ in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology	small molecule	**◎KHK2375** **Entinostat** **Oral**	HDAC Inhibitor	Breast Cancer	Phase Ⅱ in JP	Syndax	
	antibody	**KW-0761** **Mogamulizumab** **Injection**	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase Ⅱ in US, EU and others	In-House	POTELLIGENT®
Immunology/Allergy	antibody	**◎KHK4083** **Injection**	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase Ⅱ in US, EU and others	In-House	POTELLIGENT® Human Antibody-Producing Technology
	antibody	**KHK4563** **Benralizumab** **Injection**	Anti-IL-5 Receptor Humanized Antibody	Chronic Obstructive Pulmonary Disease (COPD)	Phase Ⅲ in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune
				Eosinophilic Chronic Rhinosinusitis (ECRS)	Phase Ⅱ in JP		
	antibody	**KHK4827** **Brodalumab** **Injection**	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis (axSpA)	Phase Ⅲ in JP, KR and TW	Kirin-Amgen	
	antibody	**◎ASKP1240** **Bleselumab** **Injection**	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in *de novo* kidney transplant recipients	Phase Ⅱ in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
Central Nervous System	antibody	**KW-0761** **Mogamulizumab** **Injection**	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase Ⅲ in JP	In-House	POTELLIGENT®
	small molecule	**◎KW-6356** **Oral**	Adenosine A_{2A} Receptor Antagonist	Parkinson's Disease	Phase Ⅱ in JP	In-House	
Other	antibody	**◎KRN23** **Burosumab** **Injection**	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients	Phase Ⅲ in US, CA, EU, JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH) in pediatric patients	Phase Ⅲ in US, CA, EU, AU, JP and KR		
				Tumor Induced Osteomalacia(TIO)/Epidermal Nevus Syndrome (ENS)	Phase Ⅱ in US		
					Phase Ⅱ in JP and KR		
	protein	**AMG531** **Romiplostim** **Injection**	Thrombopoietin Receptor Agonist	Aplastic Anemia	Phase Ⅱ/Ⅲ in KR	Kirin-Amgen	
				Idiopathic (Immune) Thrombocytopenic Purpura	Phase Ⅲ in CN		

Updated since Jun. 30, 2018 （Area, Stage, Filed, Approved, etc.）

◎ New Molecular Entity

Ⅴ. R&D Pipeline

Ph Ⅰ

antibody protein small molecule

As of Sep. 30, 2018

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		**◎KHK2455 Oral**	IDO 1 Inhibitor	Solid Tumor	Phase Ⅰ in US	In-House	Combination with KW-0761
		◎KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase Ⅰ in UK	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase Ⅰ/Ⅱ in US	In-House	POTELLIGENT® Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb)
Immunology/ Allergy		**◎KHK4083 Injection**	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase Ⅰ in JP	In-House	POTELLIGENT® Human Antibody-Producing Technology
				Atopic Dermatitis	Phase Ⅰ in JP		
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Autoimmune Disease	Phase I in JP	Kirin-Amgen	
Central Nervous System		**◎KHK6640 Injection**	Anti–Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase Ⅰ in EU	Licensed from Immunas Pharma	
					Phase Ⅰ in JP		
Others		**KW-3357 Antithrombin Gamma Injection**	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase Ⅰ in EU	In-House	

Updated since Jun. 30, 2018 （Area, Stage, Filed, Approved, etc.）

◎ New Molecular Entity

Updated since Jun. 30, 2018 （Area, Stage, Filed, Approved, etc.）

Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		**KW-0761 Mogamulizumab Injection**	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	Approved in US	In-House	POTELLIGENT® Additional Indication, Dosage and Administration
				Cutaneous T-cell Lymphoma	Approved in JP		
Immunology/Allergy		**KHK4827 Brodalumab Injection**	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in KR	Kirin-Amgen	
					Approved in TH		
Other		**AMG531 Romiplostim Injection**	Thrombopoietin Receptor Agonist	Aplastic Anemia	Filed in JP	Kirin-Amgen	

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		**KW-0761 Mogamulizumab Injection**	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase Ⅰ in JP	In-House	POTELLIGENT® Combination with Nivolumab (Jointly Developed with Ono Pharmaceutical)

<Appendix> Fujifilm Kyowa Kirin Biologics co. Ltd., Pipeline of Biosimilar

As of September 30th 2018

Code Name	Generic Name	Stage	Remarks
FKB327	Adalimumab （fully human anti-TNF-α monoclonal antibody）	Approved in EU	Fujifilm Kyowa Kirin Biologics Co., Ltd.
FKB238	Bevacizumab （humanized anti-VEGF monoclonal antibody）	Phase Ⅲ in US, Europe and others	Centus Biotherapeutics Ltd.(*)

* Centus Biotherapeutics Ltd. is a fifty-fifty joint venture between Fujifilm Kyowa Kirin Biologics Co., Ltd. and AstraZeneca.